#dermJC Transcript
Healthcare social media transcript of the #dermJC hashtag.
– ().
See #dermJC Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | Ade Adamson, MD MPP @AdeAdamson I'm a dermatologists at UT Austin no COI #dermjc |
 | John Barbieri, MD, MBA @DrJohnBarbieri Hi #dermjc. John Barbieri from Penn. No conflicts. |
 | Dermatology Journal Club @DermatologyJC RT @RoxanaDaneshjou: Hey #dermjc. I'm a resident at Stanford; none of my conflicts are related to this topic, but you can see a full list here: https://t.co/55sSvql7XP |
| Dermatology Journal Club @DermatologyJC RT @AdeAdamson: I'm a dermatologists at UT Austin no COI #dermjc |
| Dermatology Journal Club @DermatologyJC RT @DrJohnBarbieri: Hi #dermjc. John Barbieri from Penn. No conflicts. |
| Ade Adamson, MD MPP @AdeAdamson Just need to make sure I highlight COIs for the paper... #dermjc https://t.co/9cQn79C1WS |
| John Barbieri, MD, MBA @DrJohnBarbieri Was anyone else a little confused by Table II vs what was written in results? Results section mentions 3 serious infections in ADA qweek, but Table II has 12 (14%) #dermjc |
| Ade Adamson, MD MPP @AdeAdamson @DrJohnBarbieri yea it wasn't very clear. also the methods section writ large was hard to follow #dermJC |
| Dermatology Journal Club @DermatologyJC RT @AdeAdamson: Just need to make sure I highlight COIs for the paper... #dermjc https://t.co/9cQn79C1WS |
| John Barbieri, MD, MBA @DrJohnBarbieri While I'm glad we have these studies to support use of adalimumab/TNF-i for HS, the results of the PIONEER studies did not demonstrate not huge effect sizes and the side effect profile is potentially worrisome #dermjc |
 | Dr. Mark Abdelmalek @DrMarkReports @DrJohnBarbieri I would’ve probably been confused —- had I read it. But into this #dermjc hashtag you all have going. |
| Ade Adamson, MD MPP @AdeAdamson This is so true and I don't think many dermatologists appreciate that! #dermJC 👇🏾👇🏾👇🏾 |
| Ade Adamson, MD MPP @AdeAdamson RT @DrJohnBarbieri: While I'm glad we have these studies to support use of adalimumab/TNF-i for HS, the results of the PIONEER studies did not demonstrate not huge effect sizes and the side effect profile is potentially worrisome #dermjc |
| Dermatology Journal Club @DermatologyJC RT @AdeAdamson: This is so true and I don't think many dermatologists appreciate that! #dermJC 👇🏾👇🏾👇🏾 |
| Dermatology Journal Club @DermatologyJC RT @DrJohnBarbieri: While I'm glad we have these studies to support use of adalimumab/TNF-i for HS, the results of the PIONEER studies did not demonstrate not huge effect sizes and the side effect profile is potentially worrisome #dermjc |
| Ade Adamson, MD MPP @AdeAdamson @DrMarkABC @DrJohnBarbieri its somewhat hard to understand without reading the NEJM PIONEER trials #DermJC |
 | Steven Chen 陳持威, MD, MPH, MHPEd @DrStevenTChen #dermjc Hi all, sorry I'm late! (was on a conference call). Steven here from Boston. No conflicts. |
 | Roxana Daneshjou MD/PhD @RoxanaDaneshjou I found the lack of diversity in this study problematic. Especially given the high prevalence of hidradenitis suppurativa within skin of color populations. #dermjc https://t.co/nUj8ozSyc9 |
| Ade Adamson, MD MPP @AdeAdamson @SonaJesrani thank you for sharing your story. HS is a frustrating disease and we don't have great medicines for it. ADA can help, but is by no means a magic bullet #dermJC |
| Dermatology Journal Club @DermatologyJC RT @DrStevenTChen: #dermjc Hi all, sorry I'm late! (was on a conference call). Steven here from Boston. No conflicts. |
| Dermatology Journal Club @DermatologyJC RT @RoxanaDaneshjou: I found the lack of diversity in this study problematic. Especially given the high prevalence of hidradenitis suppurativa within skin of color populations. #dermjc https://t.co/nUj8ozSyc9 |
| John Barbieri, MD, MBA @DrJohnBarbieri RT @RoxanaDaneshjou: I found the lack of diversity in this study problematic. Especially given the high prevalence of hidradenitis suppurativa within skin of color populations. #dermjc https://t.co/nUj8ozSyc9 |
 | Leo Shmuylovich, MD PhD @leoshmu #dermJC hello Leo from Wash U, no conflicts |
| John Barbieri, MD, MBA @DrJohnBarbieri Hidradenitis seems like it could benefit from a study like DCERN to begin to parse out some of the differences between the therapeutic options available and to guide future comparative effectiveness research https://t.co/yrbyu7QiSo #dermjc |
| Roxana Daneshjou MD/PhD @RoxanaDaneshjou Have people had success with TNF-alpha inhibitors in HS? #dermjc |
| Ade Adamson, MD MPP @AdeAdamson I also had trouble wrapping my head around the PRR subset analyzed in this paper. anyone else have that problem? #dermjc |
| Dermatology Journal Club @DermatologyJC RT @DrJohnBarbieri: Hidradenitis seems like it could benefit from a study like DCERN to begin to parse out some of the differences between the therapeutic options available and to guide future comparative effectiveness research https://t.co/yrbyu7QiSo #dermjc |
| Dermatology Journal Club @DermatologyJC RT @AdeAdamson: @SonaJesrani thank you for sharing your story. HS is a frustrating disease and we don't have great medicines for it. ADA can help, but is by no means a magic bullet #dermJC |
| Ade Adamson, MD MPP @AdeAdamson The few times I tried in residency, it did not help that much #dermJC |
| Dermatology Journal Club @DermatologyJC RT @AdeAdamson: I also had trouble wrapping my head around the PRR subset analyzed in this paper. anyone else have that problem? #dermjc |
| Leo Shmuylovich, MD PhD @leoshmu #dermjc would it be fair to say that most derms taking care of HS have TNF inhibitors in the treatment ladder for patients that are not well controlled with ILK and oral antibiotics? |
| John Barbieri, MD, MBA @DrJohnBarbieri @RoxanaDaneshjou I've found infliximab (sometimes dosed more frequently) to be most effective. Have not had as much success with adalimumab, but that is somewhat expected based on trial data and given that I have often used it in patients with severe disease #dermjc |
| Ade Adamson, MD MPP @AdeAdamson RT @DrJohnBarbieri: @RoxanaDaneshjou I've found infliximab (sometimes dosed more frequently) to be most effective. Have not had as much success with adalimumab, but that is somewhat expected based on trial data and given that I have often used it in patients with severe disease #dermjc |
| John Barbieri, MD, MBA @DrJohnBarbieri @AdeAdamson I am confused that they initially give a prespecified definition for the PRR subset, but then for the statistical analysis they mention "The final PRR subpopulation was proposed on the basis of a threshold-based model". Was there some specification searching here? #dermjc |
| Steven Chen 陳持威, MD, MPH, MHPEd @DrStevenTChen @DrJohnBarbieri @RoxanaDaneshjou Infliximab is nice as it's more accurately weight-based. I haven't used anti-TNFs a ton in HS, but overall haven't been super impressed. #dermjc |
| Leo Shmuylovich, MD PhD @leoshmu #dermJC |
| Ade Adamson, MD MPP @AdeAdamson @DrJohnBarbieri thats exactly what I thought too. #dermJC #Weird |
| John Barbieri, MD, MBA @DrJohnBarbieri @DrStevenTChen @RoxanaDaneshjou I agree, weight based dosing with Infliximab I think is very helpful advantage #dermjc |
| Ade Adamson, MD MPP @AdeAdamson I'm glad others are having similar feelings #dermJC |
| Roxana Daneshjou MD/PhD @RoxanaDaneshjou RT @DrStevenTChen: @DrJohnBarbieri @RoxanaDaneshjou Infliximab is nice as it's more accurately weight-based. I haven't used anti-TNFs a ton in HS, but overall haven't been super impressed. #dermjc |
| Roxana Daneshjou MD/PhD @RoxanaDaneshjou RT @DrJohnBarbieri: @DrStevenTChen @RoxanaDaneshjou I agree, weight based dosing with Infliximab I think is very helpful advantage #dermjc |
| Leo Shmuylovich, MD PhD @leoshmu @AdeAdamson @DrJohnBarbieri What is the ideal measure for a study like this? HS can be so bothersome to some patients with only a few lesions, so lesion count alone seems to be missing something. #dermJC |
| Dermatology Journal Club @DermatologyJC RT @DrStevenTChen: @DrJohnBarbieri @RoxanaDaneshjou Infliximab is nice as it's more accurately weight-based. I haven't used anti-TNFs a ton in HS, but overall haven't been super impressed. #dermjc |
| Dermatology Journal Club @DermatologyJC RT @DrJohnBarbieri: @DrStevenTChen @RoxanaDaneshjou I agree, weight based dosing with Infliximab I think is very helpful advantage #dermjc |
| Roxana Daneshjou MD/PhD @RoxanaDaneshjou @DrJohnBarbieri @DrStevenTChen I've heard of patients going on infliximab after failing Humira. Are there any trials for that? #dermjc |
| Roxana Daneshjou MD/PhD @RoxanaDaneshjou Also wanted to mention that there is this study with using apremilast, which I've definitely never used for hidradenitis suppurativa. #dermjc Also in @JAADjournals https://t.co/jRn2Lrombw |
| Ade Adamson, MD MPP @AdeAdamson RT @RoxanaDaneshjou: @DrJohnBarbieri @DrStevenTChen I've heard of patients going on infliximab after failing Humira. Are there any trials for that? #dermjc |
| Roxana Daneshjou MD/PhD @RoxanaDaneshjou @AdeAdamson I think I had one or two patients that did well with Humira... but the others, not so much. #dermjc |
| Roxana Daneshjou MD/PhD @RoxanaDaneshjou Definitely hidradenitis suppurativa is an area that needs more research and better treatments! #dermjc |
| John Barbieri, MD, MBA @DrJohnBarbieri @RoxanaDaneshjou @DrStevenTChen https://t.co/AsbruM5WEy #dermjc |
| Roxana Daneshjou MD/PhD @RoxanaDaneshjou This is why diversity matters - why are there so few diverse patients in this trial? #dermjc https://t.co/d8w5GF62TA |
| Dermatology Journal Club @DermatologyJC RT @DrJohnBarbieri: @RoxanaDaneshjou @DrStevenTChen https://t.co/AsbruM5WEy #dermjc |
| John Barbieri, MD, MBA @DrJohnBarbieri Could be really exciting to develop a multicenter collaborative study network for both observational studies and maybe some comparative effectiveness research down the road #dermjc |
| Dermatology Journal Club @DermatologyJC RT @AdeAdamson: I'm glad others are having similar feelings #dermJC |
| Dermatology Journal Club @DermatologyJC RT @leoshmu: @AdeAdamson @DrJohnBarbieri What is the ideal measure for a study like this? HS can be so bothersome to some patients with only a few lesions, so lesion count alone seems to be missing something. #dermJC |
| Ade Adamson, MD MPP @AdeAdamson RT @RoxanaDaneshjou: This is why diversity matters - why are there so few diverse patients in this trial? #dermjc https://t.co/d8w5GF62TA |
| Ade Adamson, MD MPP @AdeAdamson RT @DrJohnBarbieri: Could be really exciting to develop a multicenter collaborative study network for both observational studies and maybe some comparative effectiveness research down the road #dermjc |
| Leo Shmuylovich, MD PhD @leoshmu @RoxanaDaneshjou @DrJohnBarbieri @DrStevenTChen Found a Phase 2 trial for infliximab here: https://t.co/6SfM9u4VMd. Sometimes I wonder if the Humira->Infliximab path is what is forced upon us by insurance requiring Humira failure before approving Infliximab... #dermjc |
| Dermatology Journal Club @DermatologyJC RT @RoxanaDaneshjou: This is why diversity matters - why are there so few diverse patients in this trial? #dermjc https://t.co/d8w5GF62TA |
| Ade Adamson, MD MPP @AdeAdamson RT @leoshmu: @RoxanaDaneshjou @DrJohnBarbieri @DrStevenTChen Found a Phase 2 trial for infliximab here: @RoxanaDaneshjou @DrJohnBarbieri @DrStevenTChen Found a Phase 2 trial for infliximab here: https://t.co/6SfM9u4VMd. Sometimes I wonder if the Humira->Infliximab path is what is forced upon us by insurance requiring Humira failure before approving Infliximab... #dermjc |
| Dermatology Journal Club @DermatologyJC RT @leoshmu: @RoxanaDaneshjou @DrJohnBarbieri @DrStevenTChen Found a Phase 2 trial for infliximab here: @RoxanaDaneshjou @DrJohnBarbieri @DrStevenTChen Found a Phase 2 trial for infliximab here: https://t.co/6SfM9u4VMd. Sometimes I wonder if the Humira->Infliximab path is what is forced upon us by insurance requiring Humira failure before approving Infliximab... #dermjc |
| Roxana Daneshjou MD/PhD @RoxanaDaneshjou RT @DrJohnBarbieri: Could be really exciting to develop a multicenter collaborative study network for both observational studies and maybe some comparative effectiveness research down the road #dermjc |
| Leo Shmuylovich, MD PhD @leoshmu @AdeAdamson @DrJohnBarbieri You guys make a great point here - the reference supporting their post-hoc analysis appears to be an abstract of some sort, maybe a poster? But even if that was a bit shady, the ADAw group results show some promise right? #dermJC |
| Roxana Daneshjou MD/PhD @RoxanaDaneshjou Also wanted to add this #dermjc |
| Dermatology Journal Club @DermatologyJC Technically we end now but no need to stop great conversations! #dermjc |
| Dermatology Journal Club @DermatologyJC RT @leoshmu: @AdeAdamson @DrJohnBarbieri You guys make a great point here - the reference supporting their post-hoc analysis appears to be an abstract of some sort, maybe a poster? But even if that was a bit shady, the ADAw group results show some promise right? #dermJC |
| Dermatology Journal Club @DermatologyJC RT @RoxanaDaneshjou: Also wanted to add this #dermjc |
#dermJC content from Twitter.